133 related articles for article (PubMed ID: 35278435)
1. Development of an SPR-based binding assay for characterization of anti-CD20 antibodies to CD20 expressed on extracellular vesicles.
Wang X; Phan MM; Sun Y; Koerber JT; Ho H; Chen Y; Yang J
Anal Biochem; 2022 Jun; 646():114635. PubMed ID: 35278435
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.
Agez M; Mandon ED; Iwema T; Gianotti R; Limani F; Herter S; Mössner E; Kusznir EA; Huber S; Lauer M; Ringler P; Ferrara C; Klein C; Jawhari A
Sci Rep; 2019 Sep; 9(1):13675. PubMed ID: 31548565
[TBL] [Abstract][Full Text] [Related]
3. Selection and characterization of single domain antibodies against human CD20.
Liu JL; Zabetakis D; Goldman ER; Anderson GP
Mol Immunol; 2016 Oct; 78():146-154. PubMed ID: 27639717
[TBL] [Abstract][Full Text] [Related]
4. FO-SPR biosensor calibrated with recombinant extracellular vesicles enables specific and sensitive detection directly in complex matrices.
Yildizhan Y; Vajrala VS; Geeurickx E; Declerck C; Duskunovic N; De Sutter D; Noppen S; Delport F; Schols D; Swinnen JV; Eyckerman S; Hendrix A; Lammertyn J; Spasic D
J Extracell Vesicles; 2021 Feb; 10(4):e12059. PubMed ID: 33664936
[TBL] [Abstract][Full Text] [Related]
5. Binding affinity determination of therapeutic antibodies to membrane protein targets: Kinetic Exclusion Assay using cellular membranes for anti-CD20 antibody.
Vaish A; Lin JS; McBride HJ; Grandsard PJ; Chen Q
Anal Biochem; 2020 Nov; 609():113974. PubMed ID: 33010205
[TBL] [Abstract][Full Text] [Related]
6. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a peptide ELISA for the detection of rituximab in serum.
Blasco H; Lalmanach G; Godat E; Maurel MC; Canepa S; Belghazi M; Paintaud G; Degenne D; Chatelut E; Cartron G; Le Guellec C
J Immunol Methods; 2007 Aug; 325(1-2):127-39. PubMed ID: 17651747
[TBL] [Abstract][Full Text] [Related]
9. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.
Golay J; Da Roit F; Bologna L; Ferrara C; Leusen JH; Rambaldi A; Klein C; Introna M
Blood; 2013 Nov; 122(20):3482-91. PubMed ID: 24106207
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Extracellular Vesicles by Surface Plasmon Resonance.
Im H; Yang K; Lee H; Castro CM
Methods Mol Biol; 2017; 1660():133-141. PubMed ID: 28828653
[TBL] [Abstract][Full Text] [Related]
11. Direct detection of nano-scale extracellular vesicles derived from inflammation-triggered endothelial cells using surface plasmon resonance.
Hosseinkhani B; van den Akker N; D'Haen J; Gagliardi M; Struys T; Lambrichts I; Waltenberger J; Nelissen I; Hooyberghs J; Molin DGM; Michiels L
Nanomedicine; 2017 Jul; 13(5):1663-1671. PubMed ID: 28366819
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab: a new class of anti-CD20 monoclonal antibody.
Gagez AL; Cartron G
Curr Opin Oncol; 2014 Sep; 26(5):484-91. PubMed ID: 25014645
[TBL] [Abstract][Full Text] [Related]
13. Magnetic nanoparticle-enhanced surface plasmon resonance biosensor for extracellular vesicle analysis.
Reiner AT; Ferrer NG; Venugopalan P; Lai RC; Lim SK; Dostálek J
Analyst; 2017 Oct; 142(20):3913-3921. PubMed ID: 28920599
[TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
15. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
16. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
17. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
Ahmadzadeh V; Farajnia S; Hosseinpour Feizi MA; Khavarinejad RA
Protein Expr Purif; 2014 Oct; 102():45-51. PubMed ID: 25088934
[TBL] [Abstract][Full Text] [Related]
18. Impact of Antigen Density on Recognition by Monoclonal Antibodies.
Bar L; Dejeu J; Lartia R; Bano F; Richter RP; Coche-Guérente L; Boturyn D
Anal Chem; 2020 Apr; 92(7):5396-5403. PubMed ID: 32200619
[TBL] [Abstract][Full Text] [Related]
19. Label-free characterization and real-time monitoring of cell uptake of extracellular vesicles.
Koponen A; Kerkelä E; Rojalin T; Lázaro-Ibáñez E; Suutari T; Saari HO; Siljander P; Yliperttula M; Laitinen S; Viitala T
Biosens Bioelectron; 2020 Nov; 168():112510. PubMed ID: 32877783
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
